A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 143 (1) , 316-324.e7
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (U19AI095219, K23HL111113, K23AI118804, K23AI125785, R01HL128241, T32AI00730, AI078908, HL117945, AI52353)
This publication has 26 references indexed in Scilit:
- Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytesBlood, 2012
- P2Y12 platelet inhibition in clinical practiceJournal of Thrombosis and Thrombolysis, 2011
- Gene‐by‐environment effect of house dust mite on purinergic receptor P2Y12 (P2RY12) and lung function in children with asthmaClinical & Experimental Allergy, 2011
- Role of the P2Y12 Receptor in the Modulation of Murine Dendritic Cell Function by ADPThe Journal of Immunology, 2010
- Cytochrome P450 Genetic Polymorphisms and the Response to PrasugrelCirculation, 2009
- EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivityAllergy, 2007
- Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmaticsAnnals of Allergy, Asthma & Immunology, 2000
- Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.Journal of Clinical Investigation, 1998
- Cromolyn Sodium Prevents Bronchoconstriction and Urinary LTE4 Excretion in Aspirin-Induced AsthmaAnnals of Allergy, Asthma & Immunology, 1998
- Leukotriene C4 Formation by Transcellular BiosynthesisaAnnals of the New York Academy of Sciences, 1994